AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs ...
AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...
Emraclidine was part of AbbVie’s acquisition of Cerevel last year, which also included Tavapadon, which recently reported positive Phase 3 results in Parkinson’s disease. The trial met its primary ...
The most promising of these is Parkinson's disease tavapadon, which in contrast to emraclidine has done well in recent late-stage trials. Eric Volkman has no position in any of the stocks mentioned.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback